Overexpression of FASN has been reported in solid tumors and hematopoietic tumors, including non-small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, and lymphoma 51, which is consistent with the results of our on-target analysis. Here, FASN is linked to prostate cancer.